Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
BiotechTV - News
00:00
Advancing CAR-T Therapy: The Case for Decentralized Manufacturing
This chapter explores the challenges of CAR T-cell therapy manufacturing and the benefits of decentralized production at hospitals. A proposal for a cloud-connected device is discussed to enhance scalability, efficiency, and real-time monitoring of treatments.
Play episode from 02:15
Transcript
